1. Prusiner SB. Prions. Proceedings of the National Academy of Sciences of the United States of America. 1998;95(23):13363-83.
2. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. Cell. 1998;93(3):337-48.
3. Kaneko K, Zulianello L, Scott M, Cooper CM, Wallace AC, James TL, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(19):10069-74.
4. Pan KM, Baldwin M, Nguyen J, Gasset M, Serban A, Groth D, et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(23):10962-6.
5. DeArmond SJ, Prusiner SB. Etiology and pathogenesis of prion diseases. The American journal of pathology. 1995;146(4):785-811.
6. Wadsworth JD, Hill AF, Beck JA, Collinge J. Molecular and clinical classification of human prion disease. British medical bulletin. 2003;66:241-54.
7. Puckett C, Concannon P, Casey C, Hood L. Genomic structure of the human prion protein gene. American journal of human genetics. 1991;49(2):320-9.
8. Viles JH, Cohen FE, Prusiner SB, Goodin DB, Wright PE, Dyson HJ. Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(5):2042-7.
9. Zahn R, Liu A, Lührs T, Riek R, von Schroetter C, López García F, et al. NMR solution structure of the human prion protein. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(1):145-50.
10. DeMarco ML, Silveira J, Caughey B, Daggett V. Structural properties of prion protein protofibrils and fibrils: an experimental assessment of atomic models. Biochemistry. 2006;45(51):15573-82.
11. Cobb NJ, Sönnichsen FD, McHaourab H, Surewicz WK. Molecular architecture of human prion protein amyloid: a parallel, in-register beta-structure. Proceedings of the National Academy of Sciences of the United States of America. 2007;104(48):18946-51.
12. Calzolai L, Zahn R. Influence of pH on NMR structure and stability of the human prion protein globular domain. Journal of Biological Chemistry. 2003;278(37):35592-6.
13. Zheng Z, Zhang M, Wang Y, Ma R, Guo C, Feng L, et al. Structural basis for the complete resistance of the human prion protein mutant G127V to prion disease. Scientific reports. 2018;8(1):13211.
14. Friedman-Levi Y, Meiner Z, Canello T, Frid K, Kovacs GG, Budka H, et al. Fatal prion disease in a mouse model of genetic E200K Creutzfeldt-Jakob disease. PLoS pathogens. 2011;7(11):e1002350.
15. Synofzik M, Bauer P, Schöls L. Prion mutation D178N with highly variable disease onset and phenotype. Journal of Neurology, Neurosurgery & Psychiatry. 2009;80(3):345-6.
16. Shamsir MS, Dalby AR. One gene, two diseases and three conformations: molecular dynamics simulations of mutants of human prion protein at room temperature and elevated temperatures. Proteins: Structure, Function, and Bioinformatics. 2005;59(2):275-90.
17. Capellari S, Parchi P, Russo CM, Sanford J, Sy M-S, Gambetti P, et al. Effect of the E200K mutation on prion protein metabolism: comparative study of a cell model and human brain. The American journal of pathology. 2000;157(2):613-22.
18. Zhang Y, Swietnicki W, Zagorski MG, Surewicz WK, Sönnichsen FD. Solution structure of the E200K variant of human prion protein: Implications for the mechanism of pathogenesis in familial prion diseases. Journal of Biological Chemistry. 2000;275(43):33650-4.
19. Gharemirshamlu FR, Bamdad K, Naeimi S. Atomic insight into prion disorder: An intricate detail gained by 0.5 μs molecular dynamics simulation of preventive G127V and deleterious D178V mutation in prion protein. Journal of cellular biochemistry. 2019;120(8):14156-64.
20. Asante EA, Smidak M, Grimshaw A, Houghton R, Tomlinson A, Jeelani A, et al. A naturally occurring variant of the human prion protein completely prevents prion disease. Nature. 2015;522(7557):478-81.
21. Sabareesan AT, Udgaonkar JB. The G126V mutation in the mouse prion protein hinders nucleation-dependent fibril formation by slowing initial fibril growth and by increasing the critical concentration. Biochemistry. 2017;56(44):5931-42.
22. Bagyinszky E, Van Giau V, Youn YC, An SSA, Kim S. Characterization of mutations in PRNP (prion) gene and their possible roles in neurodegenerative diseases. Neuropsychiatric disease and treatment. 2018;14:2067.
23. Hizume M, Kobayashi A, Teruya K, Ohashi H, Ironside JW, Mohri S, et al. Human prion protein (PrP) 219K is converted to PrPSc but shows heterozygous inhibition in variant Creutzfeldt-Jakob disease infection. Journal of Biological Chemistry. 2009;284(6):3603-9.
24. Rosenmann H, Talmor G, Halimi M, Yanai A, Gabizon R, Meiner Z. Prion protein with an E200K mutation displays properties similar to those of the cellular isoform PrP(C). Journal of neurochemistry. 2001;76(6):1654-62.
25. Paciotti R, Storchi L, Marrone A. An insight of early PrP-E200K aggregation by combined molecular dynamics/fragment molecular orbital approaches. Proteins. 2019;87(1):51-61.
26. Minikel EV, Zerr I, Collins SJ, Ponto C, Boyd A, Klug G, et al. Ascertainment bias causes false signal of anticipation in genetic prion disease. American journal of human genetics. 2014;95(4):371-82.
27. Pocchiari M, Poleggi A, Puopolo M, D’Alessandro M, Tiple D, Ladogana A. Age at Death of Creutzfeldt-Jakob disease in subsequent family generation carrying the E200K mutation of the prion protein gene. PLoS One. 2013;8(4):e60376.
28. Asante EA, Smidak M, Grimshaw A, Houghton R, Tomlinson A, Jeelani A, et al. A naturally occurring variant of the human prion protein completely prevents prion disease. Nature. 2015;522(7557):478-81.
29. Vinay Kumar C, Kumar KM, Swetha R, Ramaiah S, Anbarasu A. Protein aggregation due to nsSNP resulting in P56S VABP protein is associated with amyotrophic lateral sclerosis. Journal of theoretical biology. 2014;354:72-80.
30. Kamaraj B, Rajendran V, Sethumadhavan R, Kumar CV, Purohit R. Mutational analysis of FUS gene and its structural and functional role in amyotrophic lateral sclerosis 6. Journal of biomolecular structure & dynamics. 2015;33(4):834-44.
31. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature protocols. 2009;4(7):1073-81.
32. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al. A method and server for predicting damaging missense mutations. Nature methods. 2010;7(4):248-9.
33. Capriotti E, Fariselli P, Rossi I, Casadio R. A three-state prediction of single point mutations on protein stability changes. BMC bioinformatics. 2008;9 Suppl 2(Suppl 2):S6.
34. Capriotti E, Calabrese R, Casadio R. Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information. Bioinformatics (Oxford, England). 2006;22(22):2729-34.
35. Calabrese R, Capriotti E, Fariselli P, Martelli PL, Casadio R. Functional annotations improve the predictive score of human disease-related mutations in proteins. Human mutation. 2009;30(8):1237-44.
36. Minikel EV, Zerr I, Collins SJ, Ponto C, Boyd A, Klug G, et al. Ascertainment bias causes false signal of anticipation in genetic prion disease. The American Journal of Human Genetics. 2014;95(4):371-82.
37. Kosorinova D, Belay G, Zakova D, Stelzer M, Mitrova E. Genetic Risk Factors of Creutzfeldt-Jakob Disease in the Population of Newborns in Slovakia. Pathogens. 2021;10(4):435.
38. Jani V, Sonavane U, Joshi R. Detecting early stage structural changes in wild type, pathogenic and non-pathogenic prion variants using Markov state model. RSC advances. 2019;9(25):14567-79.
39. Studio D. Accelrys Inc. San Diego, CA. 2013.
40. DeLano WL. The PyMOL molecular graphics system. http://www pymol org. 2002.
41. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC, Hess B, et al. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX. 2015;1:19-25.
42. Schuler LD, Daura X, Van Gunsteren WF. An improved GROMOS96 force field for aliphatic hydrocarbons in the condensed phase. Journal of computational chemistry. 2001;22(11):1205-18.
43. Majumder R, Das CK, Banerjee I, Jena BC, Mandal A, Das P, et al. Screening of the Prime bioactive compounds from Aloe vera as potential anti-proliferative agents targeting DNA. Computers in Biology and Medicine. 2021:105052.
44. Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, et al. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nature genetics. 1999;22(3):231-8.
45. Collins FS, Brooks LD, Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome research. 1998;8(12):1229-31.
46. Rajasekaran R, Sudandiradoss C, Doss CGP, Sethumadhavan R. Identification and in silico analysis of functional SNPs of the BRCA1 gene. Genomics. 2007;90(4):447-52.
47. Yazar M, Özbek P. In Silico Tools and Approaches for the Prediction of Functional and Structural Effects of Single-Nucleotide Polymorphisms on Proteins: An Expert Review. OMICS: A Journal of Integrative Biology. 2021;25(1):23-37.
48. Cheng TM, Lu Y-E, Vendruscolo M, Lio' P, Blundell TL. Prediction by graph theoretic measures of structural effects in proteins arising from non-synonymous single nucleotide polymorphisms. PLoS computational biology. 2008;4(7):e1000135.
49. Doss CGP, Rajith B, Rajasekaran R, Srajan J, Nagasundaram N, Debajyoti C. In silico analysis of prion protein mutants: A comparative study by molecular dynamics approach. Cell biochemistry and biophysics. 2013;67(3):1307-18.
50. Sekijima M, Motono C, Yamasaki S, Kaneko K, Akiyama Y. Molecular dynamics simulation of dimeric and monomeric forms of human prion protein: insight into dynamics and properties. Biophysical journal. 2003;85(2):1176-85.
51. Jomah AF, Parvizpour S, Razmara J, Shamsir MS. The structural transformation comparison of the human Prion protein mutants V176G, E196A, and I215V by using molecular dynamics simulation. 2021.
52. Halder P, Mitra P. Human prion protein: exploring the thermodynamic stability and structural dynamics of its pathogenic mutants. Journal of Biomolecular Structure and Dynamics. 2021:1-17.
53. Yun S, Guy HR. Stability tests on known and misfolded structures with discrete and all atom molecular dynamics simulations. Journal of Molecular Graphics and Modelling. 2011;29(5):663-75.
54. Li Y, Yan J, Zhang X, Huang K. Disulfide bonds in amyloidogenesis diseases related proteins. Proteins: Structure, Function, and Bioinformatics. 2013;81(11):1862-73.
55. Benetti F, Legname G. New insights into structural determinants of prion protein folding and stability. Prion. 2015;9(2):119-24.
56. Shin JY, Shin JI, Kim JS, Yang YS, Shin Y-K, Kim KK, et al. Disulfide bond as a structural determinant of prion protein membrane insertion. Molecules and cells. 2009;27(6):673-80.
57. Tang Y, Wei G. Dissecting the Structural Mechanism of a Naturally Occuring Variant of the Prion Protein in Preventing Prion Disease. Biophysical Journal. 2018;114(3):234a.
58. Sanz-Hernández M, Barritt JD, Sobek J, Hornemann S, Aguzzi A, De Simone A. Mechanism of misfolding of the human prion protein revealed by a pathological mutation. Proceedings of the National Academy of Sciences. 2021;118(12).
59. Taguchi Y, Mistica AM, Kitamoto T, Schätzl HM. Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein. PLoS pathogens. 2013;9(6):e1003466.
60. Singh J, Kumar H, Sabareesan AT, Udgaonkar JB. Rational stabilization of helix 2 of the prion protein prevents its misfolding and oligomerization. Journal of the American Chemical Society. 2014;136(48):16704-7.
61. Tang Y, Yao Y, Wei G. Structural and dynamical mechanisms of a naturally occurring variant of the human prion protein in preventing prion conversion. Chinese Physics B. 2020;29(10):108710.